SBIR/STTR Research Award

Engineered aldolase for the fermentative production of L-fucose and other rare sugars.

Award identifier 91dcddc67eb768a853226788ab62e3c41a0afe56136d442e50f88d0c315b67e5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$175,813

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ZUCHEM INC.
Proposal award date
2016-03-01
Contract end date
2017-01-31
UEI
LHZKXV13TLJ7
Solicitation number
PA14-071
Topic code
300

Research abstract

DESCRIPTION provided by applicant The goal of this proposal is to develop a fermentative strategy for the large scale production of L fucose and other rare sugars L fucose deoxy L galactose is an important hexose deoxysugar found in a variety of organisms attached to an array of macromolecules These L fucose containing glycans exhibit a wide range of medicinal properties including supporting infant health L fucose containing human milk oligosaccharides anticoagulant and antithrombotic antivirus antitumor anticancer and immunomodulatory anti inflammatory blood lipids reducing antioxidant activitiy against hepatopathy uropathy and renalpathy gastric protective effects and therapeutic potential in surgery L fucose containing polymers The L fucose monomer has therapeutic properties such as inhibiting virulence factors and is also an invaluable synthetic starting material for a wide range of molecules including human milk oligosaccharides blood group antigens E and P selectin antagonists and functionalized L fucose derivatives In addition to pharmaceutical relevance L fucose also possesses topical properties attractive to the cosmetic industry including anti aging wrinkle reducing and is safe for sensitive skin Despite the impressive range of bioactivity discovered thus far L fucose remains prohibitively expensive and unavailable in the scale needed to support these applications We feel a fermentative approach is needed to meet these large scale requirements and to provide the glycoresearch community with this important building block needed to prepare scarce or unavailable glycans A key aspect of our strategy is the production of an engineered L fuculose phosphate aldolase that no longer requires the phosphorylated donor substrate dihydroxyacetone phosphate Instead the novel L fuculose phosphate aldolase FucA will catalyze the condensation between dihydroxyacetone and L lactaldehyde to form L fuculose thereby bypassing the typical sugar phosphate intermediate Through metabolic engineering we envision an E coli system capable of integrating this engineered L fuculose phosphate for the specific synthesis of L fucose In Phase I we will demonstrate the feasibility of a fermentative L fucose system by identifying and engineering a mutant FucA enzyme capable of condensing dihydroxyacetone and L lactaldehyde to form L fuculose for the ultimate production of L fucose In Phase II we will focus on the genetic and metabolic engineering of E coli for the production and accumulation of the substrates needed for the engineered L fuculose phospahte aldolase We propose a yield of g L production of L fucose after integration of the engineered L fuculose phosphate aldolase and subsequent optimizations In Phase III we will commercialize L fucose as well as other rare sugars produced by the engineered L fuculose phosphate aldolase using various acceptor aldehyde substrates PUBLIC HEALTH RELEVANCE This project is aimed toward developing a fermentative process for the large scale production of L fucose and other rare sugars L fucose is used as a synthetic building block for a wide range of pharmaceutically relevant biomolecules Additional rare sugars produced in this program will include D psicose L tagatose L fructose D ribulose L fuculose and deoxy D psicose which have applications as glucosidase inhibitors used in chemotherapy and serve as building blocks precursors to various therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

16 SBIR/STTR records share this UEI (2005–2018). Reported award amounts total $6,534,146. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.